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Edited by Laszlo NagyAbstract TheCHD family of proteins comprises ATP-dependent
chromatin remodeling enzymes, which combine chromodomains,
with SWI2/SNF2ATPase/helicasemotifs andDNA-binding capa-
bility. In the last few years, CHD proteins have drawn increased
attention, because some of them were found to form large multi-
subunit complexes, involved in transcription-related events like
gene activation, suppression, or histone modiﬁcation. We previ-
ously described the identiﬁcation of CHD6, a protein of the CHD
subfamily III. In the present study, we report that CHD6 is ex-
pressed in cells of human origin and in various mouse tissues. Sub-
cellular distribution of CHD6 is restricted to the nucleoplasm. We
further show that CHD6 colocalizes with both hypo- and hyper-
phosphorlylated forms of RNA polymerase II. CHD6 was found
to be present at sites of mRNA synthesis and to be part of a high
molecular weight complex. Moreover, we demonstrate DNA-
dependent ATPase activity of CHD6.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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DNA in eukaryotic cells exists as chromatin, a compacted
structure whose underlying basic unit is the nucleosome parti-
cle. To maintain the DNA template readily accessible for rep-
lication, transcription, and damage repair, chromatin features
many layers of complexity and regulation. ATP-dependent
chromatin remodeling proteins are one class of factors, con-
tributing to this dynamic nature of chromatin, by disrupting
or mobilizing nucleosomes in an energy-dependent manner.
A subgroup of these enzymes, the CHD family, combines
chromodomains with SWI2/SNF2 ATPase/helicase motifs
and DNA-binding capability [1,2]. Chromodomains have been
shown to recognize and bind certain histone modiﬁcations [3–
5]. The ATPase/helicase domain of CHD proteins is closely
related to Swi2, a catalytic subunit of the yeast SWI2/SNF2Abbreviations: EDTA, ethylenediamine-tetraacetic acid; DTT, dithio-
threitol; NLS, nuclear localization signal; PBS, phosphate buﬀered
saline
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and hBRM in humans. The role of the CHD DNA-binding
domains has only rudimentarily been examined for CHD1 [6].
Proteins of the CHD family appear to be present in all
eukaryotic species. Based on their phylogenetic divergence of
SWI2/SNF2 ATPase domains, CHD proteins can be grouped
into three subfamilies [7]. Currently, the best characterized
CHD proteins are CHD1 of subfamily I [1], and the Mi2
proteins CHD3/CHD4 of subfamily II [8–10]. The chroma-
tin-modifying CHD1 is conserved from yeast to human and
exhibits DNA-dependent ATPase activity [11]. It interacts with
components of the FACT, Paf1 and Spt4-Spt5 elongation
complexes and associates with DNA of actively transcribed
genes [12,13]. In yeast, Chd1 is a constituent of the two highly
homologous histone acetyltransferase (HAT) complexes
SAGA and SLIK, both of which are implicated in transcrip-
tional activation [14]. The Mi2 proteins, together with histone
deacetylases HDAC1/HDAC2 and other subunits, form the
NuRD (nucleosome remodeling histone deacetylase) complex.
Thus, NuRD links chromatin remodeling with histone deacet-
ylation activities and is generally considered to be a transcrip-
tional repressor [8–10,15].
The third CHD subfamily is deﬁned by mammalian CHD6
(formerly CHD5) and the Drosophila trithorax group protein
Kismet-L (KIS-L) [7]. KIS-L has been shown to associate with
transcriptionally active chromatin and may facilitate elonga-
tion of RNA polymerase II (RNAP II) transcribed genes dur-
ing early stages of this process [16]. Currently, much less is
known about the molecular function of mammalian subfamily
III CHD proteins. CHD9 (CreMM) appears to play a role in
regulating transcription during diﬀerentiation of osteogenic
cells [17,18]. Mutations in CHD7 cause the phenotypically
complex CHARGE syndrome in humans, highlighting the
importance of gaining insight into the molecular function of
these proteins [19].
In a previous report, we described the identiﬁcation of mam-
malian CHD6, the genomic structure of the gene and a basic
RNA expression analysis in multiple human tissues [7]. In an-
other study, we found CHD6 and hCLE (CGI-99) in a yeast
two-hybrid screen to interact with the PA subunit of inﬂuenza
virus RNA polymerase [20]. hCLE carries sequence homology
to the transcriptional activator Cdc68, a component of the
yeast FACT (facilitates chromatin transcription) complex
[21], which was found to interact with Chd1 [22]. In a recent
work, we could indeed demonstrate that hCLE is a transcrip-
tional modulator [23]. In addition to our ﬁndings, CHD6 has
been reported to form in vitro with a number of transcriptionblished by Elsevier B.V. All rights reserved.
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(PPARa-interacting cofactor), which carries HAT and tran-
scriptional activator activities [24]. The PRIC complex associ-
ates PPAR agonist-dependently to PPARa (peroxisome
proliferator activated receptor). Moreover, CHD6 was shown,
in a two-hybrid screen, to interact with Nrf2 (NF-E2-related
factor 2), a cap ‘n’ collar basic leucine zipper transcription fac-
tor [25]. Nrf2 binds to antioxidant response elements (AREs)
in the promoters of its target genes to activate transcription.
Both PPARa and Nrf2 are clinically important factors as they
are key regulators in lipid metabolism and antioxidative pro-
cesses. A possible role of CHD6 in inﬂuenza virus replication,
physical association of the protein with a PPARa multiprotein
complex and interaction with Nrf2 warrant further analysis of
this putative chromatin-remodeling protein.
Here, we present the ﬁrst molecular and enzymatic charac-
terization of CHD6. CHD6 is expressed in cell lines of human
origin and various mouse tissues. The protein is exclusively
present in the nucleoplasm, where it colocalizes with hypo-
and hyperphosphorylated forms of RNA polymerase II,
engaged in transcription preinitiation and elongation, respec-
tively. CHD6 is found in nuclear sites of mRNA synthesis
and forms part of a high molecular weight complex. Further-
more, it is a functional enzyme, which exhibits DNA-depen-
dent ATPase activity. Taken together, our data provide
strong support that CHD6 plays a role in RNAP II-mediated
transcription.2. Materials and methods
2.1. Plasmid constructions
For expression of CHD6 in mammalian cell lines, its full length
cDNA or a truncated version corresponding to amino acid residues
748–2716 (D1–747CHD6), both carrying a N-terminal triple HA-tag,
were cloned into vector pcDNA3 (Invitrogen) [7]. For production of
polyclonal antibodies against CHD6, the nucleic acid sequence corre-
sponding to amino acid residues 1915–2127 was ampliﬁed by PCR
and subcloned into vector pMAL-c (New England Biolabs).
2.2. Cell maintenance and transfection
HeLa (human uterus) and HEK293T (human kidney) cell lines were
maintained in DMEM (Invitrogen) containing 5% and 10% fetal calf
serum (Invitrogen), respectively. Cells were transfected by a standard
calcium phosphate protocol [26].
2.3. Bioinformatic analysis
The PSORTII program (www.psort.org) was used for subcellular
localization prediction. The detail output for CHD6 was: 19 ‘pat 4’,
11 ‘pat 7’ and 5 bipartite NLSs (NUCDISC subprogram); nuclear
localization with a reliability of 89% (NNCN subprogram).
PATMATDB (emboss.sourceforge.net) was used to search [GSAH]-
x-[LIVMF](3)-D-E-[ALIV]-H-[NECR] DEAH-box subfamily ATP-
dependent helicases signature.
2.4. Analysis of mouse tissues
For Western blots of diﬀerent mouse tissue extracts, a B6 wt mouse
was killed, indicated tissues were extracted and homogenized. After a
clarifying spin, the supernatant was subjected to sodium dodecyl sul-
fate gel electrophoresis.
2.5. Immunoﬂuorescence and confocal microscopy
HeLa or HEK293T cells were grown on microscope coverslips, and
ﬁxed with 3% formaldehyde in phosphate buﬀered saline (PBS). For
immunoﬂuorescence studies, permeabilized cells were incubated with
the indicated primary antibody, then, with the secondary antibody
coupled to Alexa Flour 488, or 594 (Invitrogen), and DAPI (Invitro-gen). Confocal microscopy was performed with a Bio-Rad Radiance
2100 laser scanning system on a Zeiss Axiovert 200 microscope. Images
of 1024 · 1024 pixels and 8-bit gray scale depth were sequentially taken
employing LaserSharp v5.0 software (Bio-Rad) and analyzed using
LaserPix v.4 image program (Bio-Rad).2.6. In situ transcription
The method used was based on the work of Wansink et al. [27].
HEK293T cells were grown on poly-L-lysine (Sigma) coated micro-
scope coverslips. After washing and permeabilization of the cells, cov-
erslips were incubated for 15 min at room temperature in transcription
buﬀer [50 mM Tris–HCl, 150 mM NaCl, 10 mM MgCl2, 0.5 mM eth-
ylene glycol-bis(2-aminoethylether)-N,N,N 0,N 0-tetraacetic acid, 1 mM
dithiothreitol (DTT), 1 mM phenylmethanesulfonyl ﬂuoride, 25 U/ml
RNase inhibitor rRNasin (Promega), 25% glycerol, 1.8 mM ATP,
0.5 mM CTP and GTP, 1 mM 5-bromouridine 5 0-triphosphate
(BrUTP, Sigma) at pH 7.5]. Cells were immediately ﬁxed with 3%
formaldehyde and 0.01% glutaraldehyde in PBS for 20 min at room
temperature.
2.7. ATPase assay
The ATPase assay was based on previously published methods
[11,17,28,29]. About 2.5 · 106 HEK293T cells were transfected with
12.5 lg of either plasmid pcDNA3-HA3, pcDNA3-HA3-D1–747CHD6,
or pcDNA3-HA3-CHD6. After 24 h cells were harvested, lysed and
centrifuged. The supernatant was taken for immunoprecipitation, using
a monoclonal antibody against the HA epitope (HA.11, Covance), and
polyclonal rabbit anti-mouse IgGs (Nordic Immunological Laborato-
ries) prebound to Protein A-Sepharose beads (Sigma). The beads were
washed 6 times and resuspended in 250 ll of 50 mM Tris–HCl pH 7.5,
4 mM MgCl2, 5 mM DTT, 5% glycerol, protease inhibitor cocktail
Complete without ethylenediamine-tetraacetic acid (EDTA) (Roche)
and 0.25 mg/ml bovine serum albumin. The suspension was adjusted
to a volume of 300 ll to give ﬁnal concentrations of 15 lCi/ml [c-32P]
ATP, 0.1 mM ATP (10 mM ATP for chase reactions) and indicated
concentrations of hairpin DNA (5 0-GCGCAATTGCGCTCGAC-
GATTTTTAGCGCAATTGCGC-3 0) [17,28]. The reaction mixture
was shaken overhead for 2 h at 37 C. Liberated c-32Pi was detected
by thin layer chromatography analysis [29].
2.8. Antibodies
MBP-1915–2127CHD6 was overexpressed in BL21(DE3) E. coli
cells (Novagen) and puriﬁed on an amylose column (New England
Biolabs). The fusion protein was used to generate polyclonal antisera
in rabbits (Pineda, Berlin, Germany). To immunopurify the obtained
antibodies against CHD6, MBP-1915–2127CHD6 was coupled to
CNBr-activated Sepharose 4B (Amersham), serum of a immunized
rabbit was applied to the immunoaﬃnity resin, and bound antibodies
were eluted pH-dependently. Commercial antibodies used were: mouse
aCHD3 (BD Biosciences), rat monoclonal aBrdU (Abcam), mouse
monoclonal aRNAP II 8WG16 (Covance), mouse monoclonal aR-
NAP II H5 (Covance), rabbit polyclonal aRNAP II N-20 (Santa Cruz
Biotechnology) and monoclonal aSC-35 (Sigma).3. Results
3.1. CHD6 is expressed in cells of human and mouse origin and
localizes exclusively in the nucleoplasm
To characterize expression and subcellular localization of
CHD6 by Western blot and immunoﬂuorescence, we gener-
ated a polyclonal rabbit antibody against amino acids 1915–
2127 of CHD6 (Fig. 1A). Using this antiserum we detected a
band above the 204 kDa marker by Western blot analysis of
HeLa cell extracts (Fig. 1B), which was not obtained with
the corresponding preimmune serum (data not shown). The
signal was consistent for a 305.4 kDa protein, which is the pre-
dicted molecular weight of CHD6. Only this high molecular
band was detected in extracts of HeLa and HEK293T cells
after immunopuriﬁcation of the CHD6 antiserum. Cross reac-
Fig. 1. (A) Structure of CHD6. Protein motifs are indicated as Chromo 1/2 (Chromodomains 1 and 2), SWI2/SNF2 (SWI2/SNF2 ATPase/helicase
motif), SANT [38], and TCH [40]. Bipartite NLSs predicted by PSORTII are drawn as dashed vertical lines, the DEAH-box as a vertical black box.
The dashed horizontal line (Epitope) represents the protein region used for antibody generation. D (748) indicates the ﬁrst amino acid of the N-
terminally truncated version of CHD6 (D1–747CHD6), used in the ATPase assay (see Section 3.3). (B) Detection of CHD6 in extracts of HeLa and
HEK293T cells by Western blot. Total cell extracts were analyzed by Western blot with the indicated antibodies (Serum – polyclonal rabbit antibody
against MBP-1915–2127CHD6, Immunopuriﬁed – immunopuriﬁed polyclonal rabbit antibody against MBP-1915–2127CHD6). (C) Subcellular
localization of CHD6. HeLa cells analyzed with the immunopuriﬁed antibody against CHD6 by immunoﬂuorescence microscopy (CHD6
endogenous). For detection of the HA-tagged version of CHD6, cells were transfected with pcDNA3-HA3-CHD6 and immunoﬂuorescence
microscopy was performed using an antibody against the HA epitope (HA3-CHD6 ›).
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the high speciﬁcity of the immunopuriﬁed antibody against
CHD6, which was used for all Western blot and immunoﬂuor-
ecence assays described here.
CHD proteins are thought to interact with chromatin and
their subcellular localization is generally limited to the cell nu-
cleus [6,13]. Nevertheless, CHD9 has also been detected in the
cytoplasm of human bone marrow mesenchymal cells (MSC)
[17]. We were, therefore, interested to determine whether
CHD6 can also be localized in the cytoplasm or if it is conﬁned
to the nucleus. PSORTII predicts the subcellular localization
sites of proteins based on speciﬁc amino acid motifs. Using this
program, nuclear localization was predicted for CHD6 with a
nuclear localization signal (NLS) score of 11.97 (Fig. 1A, for
details see Section 2.3). To conﬁrm the assumed nuclear local-
ization, we carried out immunoﬂuorescense microscopy. As
shown in Fig. 1C, CHD6 was exclusively localized in the nucle-
oplasm of HeLa cells, and appeared as an evenly distributed
ﬁne granular pattern. Similar results were obtained for the
overexpressed HA3-CHD6 protein, which was also conﬁnedto the nucleus. The same observations were made in HEK293T
cells (data not shown).
We previously reported low levels of CHD6 mRNA expres-
sion in various tissues of human origin [7]. Generally, expres-
sion of the CHD family of proteins in diﬀerent organs or
tissues, respectively, has not been thoroughly documented.
We therefore investigated the CHD6 protein distribution in
mouse. The epitope used to generate the antibody against
CHD6 is 80.1% identical to the same part of the mouse se-
quence, which made the antibody likely to cross-react with
the mouse protein. Indeed, the immunopuriﬁed antibody rec-
ognized a protein of the same apparent molecular weight as
human CHD6 (Fig. 2A). Using this antibody, we were thus
able to demonstrate CHD6 expression in all mouse tissues
examined, namely liver, heart, kidney, spleen and lung.
3.2. CHD6 forms a high molecular weight complex
Until now, three proteins of the CHD family (CHD1, Mi2
and KIS-L) have been shown to be parts of high molecular
weight complexes involved in transcription-related events
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gether with other subunits, the PRIC complex [24]. The assem-
bly of this high molecular complex is, however, strictly
dependent on the presence of PPARa-speciﬁc activators. Thus,
it is not clear if CHD6 is part of a permanent high molecular
weight complex in the absence of these agonists. To investigateFig. 2. (A) Presence of CHD6 in diﬀerent mouse tissues (mCHD6). Extracts
immunopuriﬁed antibody against CHD6. (B) CHD6 forms a high molecula
50 mM Tris–HCl, 150 mM NaCl, 5 mM EDTA, 0.5% Igepal CA630, protea
Sephacryl 400-HR gel ﬁltration column (12 ml bed volume). Chromatogra
trichloroacetic acid precipitated, and analyzed by Western blot with the ind
Fig. 3. (A) CHD6 is a DNA-dependent ATPase. HA3-CHD6 was overexpre
activity. As indicated no DNA (DNA ), 0.15 lMDNA (DNA +), 1.5 lMD
for chase reactions, were added. (B) The ATPase activity can be attributed to
performed as described in A, but additionally with a N-terminally truncatedthis possibility, we analyzed HeLa cell extracts by gel ﬁltration
chromatography, followed by Western blot analysis. As shown
in Fig. 2B, elution of CHD6 resulted in one discrete peak of
estimated 2–3 MDa. Since the CHD6-related protein CHD3
(Mi2) is known to form a high molecular complex (NuRD)
[10], we compared the elution proﬁles of both proteins. In con-of the indicated mouse tissues were analyzed by Western blot with the
r weight complex. HeLa cells were extracted with a buﬀer containing
se inhibitor cocktail, at pH 7.5. 300 ll of the extract were loaded to a
phy was performed by gravity ﬂow. 500 ll fractions were collected,
icated antibodies.
ssed in HEK293T cells, immunoprecipitated and analyzed for ATPase
NA (DNA ++) and 0.1 mM ATP (ATP +), or 10 mM ATP (ATP ++)
the N-terminal part of CHD6 (amino acids 1–747). Experiments were
form of CHD6.
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range from the size exclusion column, including the molecular
weight of CHD6. Taken together, CHD6 is part of a high
molecular weight complex, whose formation is independent
of the presence of PPAR agonists.
3.3. CHD6 is a DNA-dependent ATPase
Proteins of the CHD family belong to a subgroup of ATP-
dependent chromatin remodeling enzymes. ATPase activity
stimulated by DNA and/or nucleosomes has been demon-
strated for CHD1, Mi2 and CHD9 [11,17,30]. CHD6 has a
predicted SWI2/SNF2-like ATPase domain [7] encompassing
amino acids 593–602 of the protein sequence (DEAH-box,
see Section 2.3). We were, therefore, interested if CHD6 is a
functional, DNA-stimulated ATPase. A HA3-CHD6 construct
was expresssed in HEK293T cells and the immunoprecipitated
material was subsequently used for our functional analysis. A
stem–loop DNA primer has previously been shown to be very
eﬀective in stimulating ATPase activity of enzymes with SWI2/
SNF2 domains [28]. As shown in Fig. 3A, HA3-CHD6 was
eﬃciently immunoprecipitated and had indeed ATPase activ-
ity, which was stimulated upon addition of hairpin DNA. In
contrast, ATP hydrolysis could not be observed in control
experiments that either lacked HA3-CHD6 or had an excess
of ATP. To investigate if the DEAH-box is responsible for
the ATPase activity, we repeated the foregoing experiment
with a N-terminally truncated version of CHD6 (D1–Fig. 4. (A) CHD6 colocalizes with hypo- and hyperphosphorylated forms
antibodies by confocal immunoﬂuoresence microscopy. (B) Visualization of n
sites of mRNA synthesis. In situ transcription was performed as described i
addition of 5 lg/ml a-amanitin. Cells were analyzed by confocal microscopy747CHD6), lacking this motif (see Fig. 1A). As expected,
HA3-D1–747CHD6 did not show any ATPase activity
(Fig. 3B). We therefore concluded that CHD6 is a DNA-
dependent ATPase and that the activity is likely to be attrib-
uted to the ﬁrst 747 amino acids of the protein.
3.4. Localization of CHD6 overlaps with RNA polymerase II
and spots of nascent mRNA
CHD6 is part of the PRIC-complex, which is implicated in
gene activation [24], and also associates with the transcription
factor Nrf2 [25]. This suggests that CHD6 may be involved in
transcriptional processes. During the transcription cycle, the
C-terminal domain (CTD) of the largest subunit of RNAP II
is diﬀerentially phosphorylated [31]. When recruited to promo-
tors CTD is unphosphorylated [32]; after promotor clearance
and during early stages of elongation Ser-5 of the CTD is
phosphorylated and at later stages of transcriptional elonga-
tion Ser-2 becomes phosphorylated [33,34]. The distribution
of a protein relative to the diﬀerent forms of RNAP II can pro-
vide clues to its role in transcription. We used confocal immu-
noﬂuorescence microscopy to simultaneously study the
localization of CHD6 and RNAP II, hypo- and hyperphos-
phorylated at the CTD, respectively. As shown in Fig. 4A,
the distribution pattern of CHD6 appears similar to the one
of RNAP II, when the 8WG16 antibody is used. This antibody
recognizes the unphosphorylated Ser-2 site within the CTD of
RNAP II [35]. Merge analysis indicated a high degree ofof RNA polymerase II. HeLa cells were analyzed with the indicated
ascent RNA spots in HEK293T cells. CHD6 localization overlaps with
n experimental procedures, without ( a-aman.) or with (+ a-aman.)
with the indicated antibodies.
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yellow spots in the merge panel and white spots in the colocal-
ization panel, which exclusively maps the sites of colocaliza-
tion (Fig. 4A). Similar results were obtained using the H5
antibody, which recognizes the Ser-2-phosphorylated CTD.
Taken together, our data show that CHD6 localization over-
laps with RNAP II engaged in transcription preinitiation
and transcription elongation, respectively.
Although our data show that CHD6 and RNAP II colocal-
ize, we could not demonstrate a stable physical interaction be-
tween the two proteins by coimmunoprecipitation experiments
with antibodies (8WG16, H5 and N-20) directed against the
largest subunit of RNAP II (data not shown). Since the
appearance of CHD6 as a ﬁne granular pattern in immunoﬂu-
orescence microscopy reminded us, somehow, of the speckled
distribution obtained with antibodies against the splicing fac-
tor SC-35 [36], we investigated a possible colocalization of
these proteins. No apparent overlap, however, of CHD6 and
SC-35 could be found (data not shown).
An elegant in situ method established by Wansink and col-
leagues enables to visualize sites of RNA synthesis [27]. Apply-
ing this technique, 5-bromouridine 5 0-triphosphate (BrUTP) is
incorporated into nascent RNA, which can then be detected by
immunoﬂuorescence microscopy. We applied this method to
analyze in more detail the localization of CHD6 at sites of
mRNA synthesis in HEK293T cells. A punctuated pattern of
several hundred nascent-RNA sites could be visualized
throughout the nucleus, as seen in Fig. 4B. Similar patterns
have been reported for other cell types [27]. Upon addition
of a-amanitin, at concentrations inhibiting RNAP II activity,
signals in the nucleoplasm were no longer detected, and only
the sites in the nucleoli remained visible. Our confocal micros-
copy studies indicated a signiﬁcant a-amanitin-sensitive colo-
calization of CHD6 with sites of nascent RNA (Fig. 4B).
However, sites of RNA synthesis devoid of CHD6, and
CHD6 outside of RNA spots, could also be observed.4. Discussion
The ﬁnding that the CHD6 protein is present in all ﬁve
mouse tissues examined supports our hypothesis that CHD6
might have housekeeping functions [7]. Interaction of CHD6
with Nrf2, a transcription factor regulating oxidative stress re-
sponse suggests that it may play a role as a multi-organ protec-
tor [25]. Interestingly, four of the ﬁve tissues in which we found
CHD6 to be expressed (liver, kidney, spleen and lung) belong
to the group of organs dependent on Nrf2/ARE-driven detox-
iﬁcation [37]. Thus, CHD6 may be the ﬁrst member of the
CHD family linking chromatin remodeling to speciﬁc cell re-
sponses through PPAR activators, or factors inducing oxida-
tive stress.
CHD1 and the Mi2 proteins form part of high molecular
weight complexes (SAGA/SLIK and NuRD), which carry
transcription-related activities. We estimated by gel ﬁltration
chromatography the molecular weight of the CHD6 complex
to 2–3 MDa, providing further evidence that proteins of this
family generally appear to assemble in very high molecular
complexes. CHD6 eluted as a single, discrete peak from the
gel ﬁltration column, indicating that the protein is present in
only one type of high molecular weight complex – the CHD6
complex.In this work, we provided evidence that CHD6 is a func-
tional enzyme with DNA-dependent ATPase activity, similar
to other proteins of the CHD family [11,17]. Therefore,
DNA-dependent ATPase activity seems to be a common fea-
ture of proteins of this family. Truncation of the ﬁrst 747 ami-
no acids of CHD6 led to a loss of ATP hydrolysis, implying
that the ATPase activity resides in this part of the protein. This
ﬁnding agrees with the predicted DEAH-box at amino acid
positions 593–602 within the SWI/SNF2 domain of CHD6
(Fig. 1A).
CHD6 has recently been shown to interact with a PPARa
complex, and Nrf2, respectively, suggesting that it might be
a transcriptional modulator [24,25]. Characterization of the
CHD6 protein itself, however, has not been reported before.
Our subcellular localization and colocalization studies provide
further support that CHD6 plays a role in RNAP II mediated
transcriptional processes because: (I) CHD6 is localized exclu-
sively in the nucleus, but is excluded from nucleoli, the sites of
RNA polymerase I transcription (II) CHD6 colocalizes with
diﬀerently phosphorylated forms of RNAP II which are impli-
cated either in transcription preinitiation or transcription elon-
gation, and (III) CHD6 resides in loci of mRNA synthesis.
However, we also detected some sites of mRNA synthesis that
are devoid of CHD6. Further, a stable interaction between
CHD6 and RNAP II could not be demonstrated by coimmu-
noprecipitation of CHD6 with antibodies against the polymer-
ase. The same observation was previously made for KIS-L,
which nonetheless facilitates an early step in transcription
elongation [16]. In fact, none of the CHD proteins have been
shown to interact directly with RNAP II.
It is noteworthy that CHD6 and CHD9, contrary to other
members of the CHD family, exhibit SANT domains. SANT
domains can play crucial roles for the activity of HAT and
HDAC complexes, respectively, involved in transcriptional
regulation [38]. Recently, PPARc has been shown to recruit
the SANT domain-containing factor SMRT (silencing media-
tor of retinoid and thyroid hormone receptors), resulting in a
downregulation of PPARc-mediated transcriptional activity
[39].
Combined, our data portray CHD6 as a factor that does not
form part of the basic transcription machinery but may be
modulating only a subset of genes. A comprehensive conclu-
sion, which step of transcription is promoted and a possible
role of CHD6 in the replication of inﬂuenza virus, necessarily
requires further analysis. Genetic studies in mice are underway
to evaluate the biological role and clinical relevance of this, un-
til now, uncharacterized DNA-stimulated ATPase.
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